Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 10
Submit an article Journal homepage
4,757
Views
11
CrossRef citations to date
0
Altmetric
Hematology

Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP

Joanna DavisUniversity of Miami Hemophilia Treatment Center, Miami, FL, USA;
,
Songkai YanCSL Behring, King of Prussia, PA, USA; Correspondence[email protected]
,
Tadashi MatsushitaDepartment of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan;
,
Lorenzo AlberioDivision of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV), Lausanne, Switzerland;
,
Paul BassettMeridian HealthComms, Cheshire, UK;
&
Elena SantagostinoFoundation IRCCS Ca’ Granda Maggiore Hospital Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
Pages 1014-1021 | Received 18 Apr 2019, Accepted 07 May 2019, Published online: 05 Jun 2019

References

  • Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1–47.
  • Franchini M. Current management of hemophilia B: recommendations, complications and emerging issues. Expert Rev Hematol. 2014;7:573–581.
  • Forsyth AL, Rivard GE, Valentino LA, et al. Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond. Haemophilia. 2012;18:112–119.
  • Djambas Khayat C. Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B. J Blood Med. 2016;7:275–282.
  • Ljung R, Gretenkort Andersson N. The current status of prophylactic replacement therapy in children and adults with haemophilia. Br J Haematol. 2015;169:777–786.
  • Mahdi AJ, Obaji SG, Collins PW. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol. 2015;169:768–776.
  • Mannucci PM, Franchini M. Emerging drugs for hemophilia B. Expert Opin Emerg Drugs. 2014;19:407–414.
  • Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127:1761–1769.
  • Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–2323.
  • Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124:3880–3886.
  • Iorio A, Krishnan S, Myren KJ, et al. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption. J Med Econ. 2017;20:337–344.
  • Higgins J, Deeks J. Chapter 7: Selecting studies and collecting data. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011): The Cochrane Collaboration. Chichester, England: John Wiley & Sons, Ltd.; 2011.
  • Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007;13:233–243.
  • Oldenburg J, Carcao M, Lentz SR, et al. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: pooled data from the paradigm trials. Haemophilia. 2018;24:911–920.
  • Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia. 2016;22:381–388.
  • Windyga J, Lissitchkov T, Stasyshyn O, et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level </=2%) haemophilia B. Haemophilia. 2014;20:15–24.
  • Solano Trujillo MH, Stasyshyn O, Rusen L, et al. Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326). Haemophilia. 2014;20:674–681.
  • Collins PW, Quon DVK, Makris M, et al. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia. 2018;24:104–112.
  • Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001;7:392–396.
  • Armstrong EP, Malone DC, Krishnan S, et al. Adherence to clotting factors among persons with hemophilia A or B. Hematology. 2015;20:148–153.
  • Yeung CH, Santesso N, Pai M, et al. Care models in the management of haemophilia: a systematic review. Haemophilia. 2016;22:31–40.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.